ASCO 2021 – Martin Reck
Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.
Here is the full ASCO 2021 report.
More posts
Opening up new vistas for patients with SCLC
Opening up new vistas for patients with SCLC Cisplatin vs. carboplatin in LS-SCL
Enhancing immunosupportive mechanisms via anti-angiogenesis
Enhancing immunosupportive mechanisms via anti-angiogenesis Treatment with anti-a
How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer?
How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer
Immunotherapy: from predictive factors to antibiotics
Immunotherapy: from predictive factors to antibiotics Update of CheckMate 9LA Bas
KRAS, MET, ROS1, HER2: current perspectives
KRAS, MET, ROS1, HER2: current perspectives CodeBreaK100: sotorasib Approximately
EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutations
EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutati
